Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees - Seite 2
Darin Leigh, Chief Commercial Officer at Mainz Biomed, added: “Early detection is key to increasing treatment options as well as survival rates for colorectal cancer patients. Screening at regular intervals is essential to detecting the disease in early stages where it can be successfully treated and dramatically improve patient outcomes. We applaud Bantleon for their highly progressive approach to the wellbeing of their employees and look forward to our continued collaboration as we work to spare more people from the devastating impacts of this disease.”
Please follow us to stay up to date:
LinkedIn
X
(Previously Twitter)
Facebook
About ColoAlert
ColoAlert, Mainz Biomed’s flagship product, delivers high sensitivity and specificity in a user-friendly, at-home colorectal cancer (CRC) screening kit. This non-invasive test can be indicative of
tumors as determined by analyzing tumor DNA, offering better early detection than fecal occult blood tests (FOBT). Based on PCR-technology, ColoAlert detects more cases of colorectal cancer
than other stool tests and allows for an earlier diagnosis (Dollinger et al., 2018). The product is commercially available in select EU countries through a network of leading independent laboratories, corporate health
programs and via direct sales. To receive marketing approval in the US, ColoAlert will be evaluated in the FDA-registration trial ‘ReconAAsense.’ Once approved in the US, the Company’s
commercial strategy is to establish scalable distribution through a collaborative partner program with regional and national laboratory service providers across the country.
Lesen Sie auch
About Colorectal Cancer
Colorectal cancer (CRC) is the third most common cancer globally, with more than 1.9 million new cases reported in 2020, according to World Cancer Research Fund International. The US Preventive
Services Task Force recommends that screening with stool DNA tests such as ColoAlert should be conducted once every three years starting at age 45. Each year in the US, 16.6 million
colonoscopies are performed. However, roughly one-third of US residents aged 50-75 have never been screened for colon cancer. This gap in screening represents a $4.0B+ total market opportunity in
the US.